Newsletter Subject

Daily Headlines: Republicans Release ACA Replacement Plan

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Tue, Mar 7, 2017 12:05 PM

Email Preheader Text

Daily Headlines March 7, 2017 Additional Resources Industry Resources [Repatha? MDs: Help Get Pati

Daily Headlines March 7, 2017 [Republicans Release ACA Replacement Plan]( [Canadian Docs Bitterly Divided]( [Below-Ankle Interventions Promising for Foot Salvage]( [Psoriasis Responds After Biologic Failure]( [Improving Addiction Care: HealthLeaders Media]( Additional Resources [Diagnosis and Treatment of Relapsed Myeloma]( [AML: Beware of Pre-leukemic Clones Surviving Chemotherapy]( [Support for Omitting ALND in Early Breast Cancer]( Industry Resources [Repatha™ (evolocumab) MDs: Help Get Patients Started on Repatha™]( [Myelomatosis A Treatment Option For Previously Treated Multiple Myeloma. HCP Site.]( [Multiple Myeloma HCP Site Learn about a Treatment Option For Multiple Myeloma Relapses]( Recent Headlines [Long-term Low-dose Steroids OK in Early RA]( CME/CE [D.C. Week: Trump Shares Broad Outline of for Trumpcare]( [D.C. Week: Trump Shares Broad Outline of Trumpcare]( [Love of Urine: That's Improbable!]( [The Numbers on Hospial Staffing and Nurse Salary]( ADVERTISEMENT This Week's Survey [ACA Repeal: Too Tough to Tackle?]( [President Trump admitted that]([healthcare is more complicated]( than he thought, in explaining why neither his team nor Republicans in Congress had yet developed a unified plan to replace the Affordable Care Act CME Spotlights [Gynecologic Cancers @Point of Care]( [Source: @Point of Care]( [MDS and Acute Myeloid Leukemia (MDS and AML) @Point of Care]( [Source: @Point of Care]( [Prostate Cancer @Point of Care]( [Source: @Point of Care]( [Skin Cancers @Point of Care]( [Source: @Point of Care]( [Are biosimilars as safe and effective as reference products?]( [Source: France Foundation]( [Playing The Offense In Advanced Basal Cell Carcinoma: A Team Approach To Treatment And Management]( [Source: RMEI Medical Education]( [Clinical Convergenceu2120: Patient and Provider Perspectives in NSCLC: Follow-up Visits]( [Source: RMEI Medical Education]( [Clinical Convergence℠: Patient and Provider Perspectives in NSCLC: Initial Visits]( [Source: RMEI Medical Education]( [A Patient-Centric, Performance Measures-Based Approach to NSCLC]( [Source: RMEI Medical Education]( [Breast Cancer @POC w/Watson]( [Source: @Point of Care]( More of Today's Stories [SMART on FHIR Apps for EHRs Help Enable Interoperability]( [No Heart Surgeon Match Day for Major Medical Center]( [Coated Balloons Found Less Effective in Women for Peripheral Lesions]( [Cimzia Passes Muster in Two Psoriasis Trials]( [Peanut Patch Shows Sustained Response in Extention Trial]( CME/CE [Migraine Tied to Neck Artery Dissection in Stroke]( CME/CE [FDA Lifts Trial Hold on Leukemia Drug (Reuters)]( [AAAAI: Oral Immunotherapy for Gluten Allergy Passes Test]( CME/CE [CardioBrief: A Call for More CAC Screening Faces Pushback]( [CardioBreak: Bifurcation Stent Approved; Drone AED Delivery; Fraud Arrests]( [Meta-Analysis: Biodegradable Polymers Don't Cut Stent Risks]( CME/CE [Evidence that Threats to Halt $$ for PCI Overuse Worked]( CME/CE [Dramatic Responses to Biologic in Atopic Dermatitis]( [Secukinumab Benefits Hold Up for 2 Years]( CME/CE [Bacterial Spray Promising for Keratosis Pilaris]( [Mixed Infant Feeding May Up Risk for Food Allergy]( [Vitamin D: Can It Lower Respiratory Infection Risk?]( More news from MedPage Today® Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. © 2016 Medpage Today, LLC. All rights reserved. Use of this site constitutes acceptance of the [MedPageToday.com]( [terms of use]( and [privacy policy](. The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Medpage Today is located at 345 Hudson Street, New York, NY 10014 [Remove me from this list](lst=Daily%20Headlines) [Manage my e-mail settings](

Marketing emails from medpagetoday.com

View More
Sent On

30/06/2024

Sent On

30/06/2024

Sent On

29/06/2024

Sent On

29/06/2024

Sent On

28/06/2024

Sent On

28/06/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.